[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 17 of about 17
1. Grundy RG, Wilne SH, Robinson KJ, Ironside JW, Cox T, Chong WK, Michalski A, Campbell RH, Bailey CC, Thorp N, Pizer B, Punt J, Walker DA, Ellison DW, Machin D, Children's Cancer and Leukaemia Group (formerly UKCCSG) Brain Tumour Committee: Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/SIOP CNS 9204 trial. Eur J Cancer; 2010 Jan;46(1):120-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/SIOP CNS 9204 trial.
  • BACKGROUND: Radiotherapy is an effective adjuvant treatment for brain tumours arising in very young children, but it has the potential to damage the child's developing nervous system at a crucial time - with a resultant reduction in IQ leading to cognitive impairment, associated endocrinopathy and risk of second malignancy.
  • We aimed to assess the role of a primary chemotherapy strategy in avoiding or delaying radiotherapy in children younger than 3 years with malignant brain tumours other than ependymoma, the results of which have already been published.
  • METHODS: Ninety-seven children were enrolled between March 1993 and July 2003 and, following diagnostic review, comprised: medulloblastoma (n=31), astrocytoma (26), choroid plexus carcinoma [CPC] (15), CNS PNET (11), atypical teratoid/rhabdoid tumours [AT/RT] (6) and ineligible (6).
  • FINDINGS: Over all diagnostic groups the cumulative progression rate was 80.9% at 5 years while the corresponding need-for-radiotherapy rate for progression was 54.6%, but both rates varied by tumour type.
  • The 5-year EFS for non-brainstem high-grade gliomas [HGGs] was 13.0% (CI: 2.2-33.4) and the OS was 30.9% (CI: 11.5-52.8).
  • INTERPRETATION: The outcome for very young children with brain tumours is dictated by degree of surgical resection and histological tumour type and underlying biology as an indicator of treatment sensitivity.
  • Desmoplastic/nodular sub-type of medulloblastoma has a better prognosis than classic histology, despite traditional adverse clinical features of metastatic disease and incomplete surgical resection.
  • This study highlights the differing therapeutic challenges presented by the malignant brain tumours of early childhood, the importance of surgical approaches and the need to explore individualised brain sparing approaches to the range of malignant brain tumours that present in early childhood.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy
  • [MeSH-minor] Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Astrocytoma / surgery. Child, Preschool. Choroid Plexus Neoplasms / drug therapy. Choroid Plexus Neoplasms / radiotherapy. Choroid Plexus Neoplasms / surgery. Disease Progression. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infant. Male. Medulloblastoma / drug therapy. Medulloblastoma / radiotherapy. Medulloblastoma / surgery. Neuroectodermal Tumors, Primitive / drug therapy. Neuroectodermal Tumors, Primitive / radiotherapy. Neuroectodermal Tumors, Primitive / surgery. Radiotherapy, Adjuvant / methods. Survival Analysis. Teratoma / drug therapy. Teratoma / radiotherapy. Teratoma / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19818598.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


2. Hofman R, Rosingh HJ: Unilateral hearing loss as primary symptom of craniopharyngioma in a six-year-old girl. J Laryngol Otol; 2008 Mar;122(3):e10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unilateral hearing loss as primary symptom of craniopharyngioma in a six-year-old girl.
  • Magnetic resonance scanning revealed a massive, cystic craniopharyngioma exerting pressure on the patient's ventricular system and brainstem and also invading the internal acoustic canal.
  • [MeSH-major] Craniopharyngioma / complications. Hearing Loss, Unilateral / etiology. Pituitary Neoplasms / complications
  • [MeSH-minor] Child. Craniotomy / methods. Female. Humans. Reflex, Babinski / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18252012.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 6
  •  go-up   go-down


3. Blaney S, Berg SL, Pratt C, Weitman S, Sullivan J, Luchtman-Jones L, Bernstein M: A phase I study of irinotecan in pediatric patients: a pediatric oncology group study. Clin Cancer Res; 2001 Jan;7(1):32-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myelosuppression was the primary DLT in heavily pretreated patients, and diarrhea was the DLT in less-heavily pretreated patients.
  • Stable disease (4-20 cycles) was observed in seven patients with a variety of malignancies including neuroblastoma, pineoblastoma, glioblastoma, brainstem glioma, osteosarcoma, hepatoblastoma, and a central nervous system rhabdoid tumor.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Enzyme Inhibitors / therapeutic use. Neoplasms / drug therapy. Topoisomerase I Inhibitors
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Hematologic Tests. Humans. Infant. Infusions, Intravenous. Male. Toxicity Tests. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11205914.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / MO1RR00188; United States / NCI NIH HHS / CA / U01CA57745
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Enzyme Inhibitors; 0 / Topoisomerase I Inhibitors; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


Advertisement
4. Packer RJ, Krailo M, Mehta M, Warren K, Allen J, Jakacki R, Villablanca JG, Chiba A, Reaman G: A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas. Cancer; 2005 Nov 1;104(9):1968-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas.
  • BACKGROUND: Ninety percent of children with diffuse, intrinsic brainstem tumors will die within 18 months of diagnosis.
  • Carboplatin is antineoplastic and radiosensitizing; however, its delivery to the primary tumor site is problematic.
  • RMP-7 is a bradykinin analog that causes selective permeability of the blood-brain-tumor interface.
  • The objective of this Phase I study was to determine the toxicity and feasibility of delivering RMP-7 and carboplatin for 5 successive days during radiotherapy to children with newly diagnosed, diffuse, intrinsic brainstem gliomas.
  • Local radiotherapy, in dose fractions of 180 centigrays (cGy) per day (to a total dose of 5940 cGy), was given within 4 hours of completion of drug delivery.
  • CONCLUSIONS: The results of this study confirmed the feasibility of giving RMP-7 and carboplatin daily during radiotherapy to children with brainstem tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bradykinin / analogs & derivatives. Brain Stem Neoplasms / drug therapy. Brain Stem Neoplasms / radiotherapy. Carboplatin / therapeutic use. Glioma / drug therapy. Glioma / radiotherapy
  • [MeSH-minor] Child. Child, Preschool. Combined Modality Therapy. Drug Administration Schedule. Feasibility Studies. Female. Humans. Male. Radiotherapy / adverse effects. Radiotherapy Dosage. Survival Rate. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 16177987.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 159768-75-9 / RMP 7; BG3F62OND5 / Carboplatin; S8TIM42R2W / Bradykinin
  •  go-up   go-down


5. Warren KE, Frank JA, Black JL, Hill RS, Duyn JH, Aikin AA, Lewis BK, Adamson PC, Balis FM: Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors. J Clin Oncol; 2000 Mar;18(5):1020-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors.
  • We measured the relative tumor concentrations of these biochemical markers in children with recurrent brain tumors and evaluated their potential prognostic significance.
  • PATIENTS AND METHODS: (1)H-MRSI was performed on 27 children with recurrent primary brain tumors referred to our institution for investigational drug trials.
  • Diagnoses included high-grade glioma (n = 10), brainstem glioma (n = 7), medulloblastoma/peripheral neuroectodermal tumor (n = 6), ependymoma (n = 3), and pineal germinoma (n = 1). (1)H-MRSI was performed on 1.
  • The concentrations of choline (Cho) and N-acetyl-aspartate (NAA) in the tumor and normal brain were quantified using a multislice multivoxel method, and the maximum Cho:NAA ratio was determined for each patient's tumor.
  • RESULTS: The maximum Cho:NAA ratio ranged from 1.1 to 13.2 (median, 4.5); the Cho:NAA ratio in areas of normal-appearing brain tissue was less than 1.0.
  • The maximum Cho:NAA ratio for each histologic subtype varied considerably; approximately equal numbers of patients within each tumor type had maximum Cho:NAA ratios above and below the median.
  • CONCLUSION: The maximum tumor Cho:NAA ratio seems to be predictive of outcome in children with recurrent primary brain tumors and should be evaluated as a prognostic indicator in newly diagnosed childhood brain tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Magnetic Resonance Spectroscopy / methods
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Child. Child, Preschool. Humans. Neoplasm Recurrence, Local. Pilot Projects. Prognosis. Protons

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10694552.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protons
  •  go-up   go-down


6. Wasita B, Kamitani H, Kinoshita Y, Mamun MH, Watanabe T: A rat glioblastoma model with diffuse leptomeningeal gliomatosis induced by intracarotid injection of C6 glioma cells. Neurol Res; 2009 Jun;31(5):453-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: A reproducible brain tumor model using experimental animals is required to study biological behavior and develop more potent antineoplastic drugs and effective therapeutic modalities.
  • METHODS: Intracarotid injection of 1 x 10(7) C6 glioma cells in Wistar rats was performed to establish a primary diffuse leptomeningeal gliomatosis model.
  • Ki-67 and matrix metalloproteinases (MMPs) immunohistochemistry staining were used to study the biological behavior of the developed tumor.
  • The glioma mass distributed throughout the ventricles, the leptomeningeal regions in the brain and the brainstem, with typical pathological features of glioblastoma.
  • This established animal model is a novel model of primary diffuse leptomeningeal gliomatosis.
  • [MeSH-major] Disease Models, Animal. Glioblastoma / pathology. Glioma / pathology. Meningeal Neoplasms / pathology
  • [MeSH-minor] Animals. Biomarkers, Tumor / metabolism. Cachexia / physiopathology. Cell Line, Tumor. Disease Progression. Immunohistochemistry. Intracranial Pressure. Ki-67 Antigen / metabolism. Male. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Neoplasm Invasiveness. Neoplasm Transplantation. Rats. Rats, Wistar

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19309540.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.24 / Mmp2 protein, rat; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


7. Warren K, Jakacki R, Widemann B, Aikin A, Libucha M, Packer R, Vezina G, Reaman G, Shaw D, Krailo M, Osborne C, Cehelsky J, Caldwell D, Stanwood J, Steinberg SM, Balis FM: Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group. Cancer Chemother Pharmacol; 2006 Sep;58(3):343-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group.
  • BACKGROUND: [corrected] Lobradimil is a synthetic bradykinin analog that rapidly and transiently increases the permeability of the blood-brain barrier (BBB).
  • The combination of lobradimil and carboplatin was studied in pediatric patients with primary brain tumors in a phase II trial, the primary endpoints of which were to estimate the response rate and time to disease progression.
  • PATIENTS AND METHODS: Patients were stratified by histology into five cohorts: brainstem glioma, high-grade glioma, low-grade glioma, medullobastoma/primitive neuroectodermal tumor (PNET), and ependymoma.
  • No objective responses were observed in the brainstem glioma (n=12) and high-grade glioma (n = 9) cohorts, although two patients with high-grade glioma had prolonged disease stabilization (>6 months).
  • CONCLUSION: The combination of lobradimil and carboplatin was inactive in childhood high-grade gliomas and brainstem gliomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood-Brain Barrier / metabolism. Brain Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bradykinin / administration & dosage. Bradykinin / adverse effects. Bradykinin / analogs & derivatives. Bradykinin / therapeutic use. Carboplatin / administration & dosage. Carboplatin / adverse effects. Carboplatin / therapeutic use. Child. Child, Preschool. Cohort Studies. Drug Administration Schedule. Humans. Infusions, Intravenous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16408203.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 159768-75-9 / RMP 7; BG3F62OND5 / Carboplatin; S8TIM42R2W / Bradykinin
  •  go-up   go-down


8. Fouladi M, Nicholson HS, Zhou T, Laningham F, Helton KJ, Holmes E, Cohen K, Speights RA, Wright J, Pollack IF, Children's Oncology Group: A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study. Cancer; 2007 Dec 1;110(11):2535-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study.
  • BACKGROUND: An open-label Phase II study of tipifarnib was conducted to evaluate its safety and efficacy in children with recurrent or refractory medulloblastoma (MB)/primitive neuroectodermal tumor (PNET), high-grade glioma (HGG), and diffuse intrinsic brainstem glioma (BSG).
  • The primary objective was to estimate the sustained response rate in all strata.
  • CONCLUSIONS: Tipifarnib tolerated well but had little activity as a single agent in children with recurrent central nervous system malignancies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Brain Stem Neoplasms / drug therapy. Glioma / drug therapy. Medulloblastoma / drug therapy. Quinolones / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease Progression. Female. Humans. Male. Neuroectodermal Tumors / drug therapy. Treatment Outcome


9. Buss A, Assmus A, Weidemann J, Sellhaus B, Lorenzen J, Block F: [Diagnosis of an initial infratentorial central nervous system B-cell lymphoma during prolonged cortisone medication]. Nervenarzt; 2004 Dec;75(12):1217-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis of an initial infratentorial central nervous system B-cell lymphoma during prolonged cortisone medication].
  • We present a patient with primary central nervous system B-cell lymphoma.
  • The patient was dismissed with the primary diagnosis of autoimmune encephalitis of the brainstem and put on oral corticosteroids.
  • Four months later, his health status had deteriorated, and at that time diagnostic methods pointed to a cerebral lymphoma.
  • The patient was treated with whole brain radiotherapy.
  • [MeSH-major] Adrenal Cortex Hormones / therapeutic use. Autoimmune Diseases of the Nervous System / diagnosis. Autoimmune Diseases of the Nervous System / drug therapy. Brain Neoplasms / diagnosis. Diagnostic Errors. Encephalitis / diagnosis. Encephalitis / drug therapy. Lymphoma, B-Cell / diagnosis
  • [MeSH-minor] Aged. Anti-Inflammatory Agents / administration & dosage. Diagnosis, Differential. Humans. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Encephalitis.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Neurol Neurosurg. 1992;94(1):1-5 [1321691.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(1):21-8 [2113737.001]
  • [Cites] J Clin Neuroophthalmol. 1983 Jun;3(2):127-30 [6309914.001]
  • [Cites] Cancer. 1994 Aug 15;74(4):1383-97 [8055462.001]
  • [Cites] J Neurooncol. 2001 Jan;51(2):129-31 [11386409.001]
  • [Cites] J Neurol Sci. 2000 Dec 1;181(1-2):1-12 [11099705.001]
  • [Cites] Am J Surg Pathol. 1994 Sep;18(9):931-7 [8067514.001]
  • [Cites] Neurology. 2001 Aug 28;57(4):716-8 [11524489.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2407-14 [12805341.001]
  • [Cites] Neurology. 1989 Sep;39(9):1190-6 [2788832.001]
  • [Cites] Nervenarzt. 2002 Aug;73(8):779-84 [12242968.001]
  • [Cites] Clin Imaging. 2002 Jul-Aug;26(4):237-42 [12140152.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4615-7 [12488403.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):271-3 [11796784.001]
  • [Cites] Neurology. 2001 Aug 14;57(3):393-6 [11515505.001]
  • [Cites] Acta Neuropathol. 1990;80(6):629-34 [2275339.001]
  • (PMID = 15224176.001).
  • [ISSN] 0028-2804
  • [Journal-full-title] Der Nervenarzt
  • [ISO-abbreviation] Nervenarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anti-Inflammatory Agents
  •  go-up   go-down


10. Packer RJ, Krailo M, Mehta M, Warren K, Allen J, Jakacki R, Villablanca JG, Chiba A, Reaman G: Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas. Cancer; 2005 Sep 15;104(6):1281-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas.
  • BACKGROUND: Ninety percent of children with diffuse intrinsic brainstem tumors will die within 18 months of diagnosis.
  • However, delivery to the primary tumor site is problematic.
  • RMP-7 is a bradykinin analog that causes selective permeability of the blood-brain-tumor interface.
  • Local radiotherapy (5940 centigrays) was given within 4 hours of completion of drug delivery.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Stem Neoplasms / therapy. Carboplatin / administration & dosage. Glioma / therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16078267.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 159768-75-9 / RMP 7; BG3F62OND5 / Carboplatin; S8TIM42R2W / Bradykinin
  •  go-up   go-down


11. Ohno M, Natsume A, Fujii M, Ito M, Wakabayashi T: Interferon-beta, MCNU, and conventional radiotherapy for pediatric patients with brainstem glioma. Pediatr Blood Cancer; 2009 Jul;53(1):37-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-beta, MCNU, and conventional radiotherapy for pediatric patients with brainstem glioma.
  • BACKGROUND: Most children with brainstem glioma die within 2 years of diagnosis, and the median survival time for patients with this condition is less than 1 year.
  • The role of chemotherapy in the treatment of children with brainstem glioma is not well defined.
  • The primary aim of this study is to evaluate the effects of treatment with interferon-beta (IFN-beta), ranimustine (MCNU), and radiotherapy (IMR therapy) administered to brainstem glioma patients treated at our institution.
  • PROCEDURES: We retrospectively reviewed 15 patients who were newly diagnosed to have brainstem tumors and were administered IFN-beta (1-2 MIU/day, days 1-7; 0.5-1 MIU/day, days 8-14) and MCNU (80 mg/m(2) on day 2) concurrently with conventional radiotherapy.
  • CONCLUSIONS: The IMR combination therapy is well tolerated and may be a promising treatment for brainstem glioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Stem Neoplasms / drug therapy. Brain Stem Neoplasms / radiotherapy. Glioma / drug therapy. Glioma / radiotherapy
  • [MeSH-minor] Adolescent. Carboplatin / administration & dosage. Child. Child, Preschool. DNA Methylation / drug effects. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Interferon-beta / administration & dosage. Magnetic Resonance Imaging. Male. Nitrosourea Compounds / administration & dosage. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • (PMID = 19260101.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nitrosourea Compounds; 6PLQ3CP4P3 / Etoposide; 77238-31-4 / Interferon-beta; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; BG3F62OND5 / Carboplatin; RYH2T97J77 / ranimustine
  •  go-up   go-down


12. Dea N, Borduas M, Kenny B, Fortin D, Mathieu D: Safety and efficacy of Gamma Knife surgery for brain metastases in eloquent locations. J Neurosurg; 2010 Dec;113 Suppl:79-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of Gamma Knife surgery for brain metastases in eloquent locations.
  • OBJECT: Brain metastases are the most frequently occurring cerebral tumors.
  • Gamma Knife surgery (GKS) is a recognized treatment modality for brain metastases.
  • This study was undertaken to assess the safety and efficacy of GKS, specifically for brain metastases in eloquent locations.
  • METHODS: Charts of patients harboring brain metastases that were treated by GKS at the Centre Hospitalier Universitaire de Sherbrooke between August 2004 and April 2008 were reviewed.
  • Planning images were assessed by an independent neurosurgeon to assess tumor location.
  • Eloquent locations included the primary motor, somatosensory, speech, and visual cortices; the basal ganglia; the thalamus; and the brainstem.
  • Data on survival, tumor response, and complications were analyzed and compared with data published on surgical treatment of these lesions.
  • Non-small cell lung cancer was the most common primary tumor (63.2% of metastases), followed by small cell lung (8.4%), breast (7.4%), colorectal (5.3%), and renal cell (4.2%) cancers, as well as melanoma (4.2%).
  • The median dose to the tumor margin was 18 Gy (range 14-24 Gy).
  • The median time to tumor progression was 16 months.
  • Higher margin dose (p = 0.002), the absence of edema (p = 0.009), and the non-small cell lung cancer tissue type (p = 0.035) positively affected response rates.
  • Steroid medications were no longer used in 46% of patients after GKS.
  • CONCLUSIONS: Gamma Knife surgery is safe and effective for brain metastases located in eloquent areas.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery. Radiosurgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21218534.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Terasaki M, Bouffet E, Katsuki H, Fukushima S, Shigemori M: Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors. Surg Neurol; 2008 Jan;69(1):46-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The aim of this study was to determine the response and toxicity of patients with recurrent or treatment-induced brain tumors to TMZ and oral VP-16.
  • METHODS: Eleven patients with recurrent or treatment-induced malignant CNS tumors, including treatment-induced PNET (in 1 patient), brainstem glioma (in 3 patients; 1 with treatment-induced, 2 with recurrence), recurrent anaplastic astrocytoma (in 3 patients), and recurrent glioblastoma (in 4 patients) were evaluated in a pilot study of TMZ and oral VP-16 chemotherapy.
  • Five (45%) of 11 patients showed a PR to treatment.
  • The histologic subtype of the tumor, its location, and its maximum response to chemotherapy did not have an impact on the duration of disease control.
  • CONCLUSION: This limited pilot study confirms the innocuousness and the activity of the combination of TMZ and oral VP-16 in recurrent malignant brain tumors.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Etoposide / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Neoplasms, Neuroepithelial / drug therapy. Neoplasms, Second Primary / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Aged. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Pilot Projects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18054615.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


14. Dreyer ZE, Kadota RP, Stewart CF, Friedman HS, Mahoney DH, Kun LE, McCluggage CW, Burger PC, Kepner J, Heideman RL, Pediatric Oncology Group: Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237. Neuro Oncol; 2003 Oct;5(4):261-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237.
  • In previous reports, the alcohol metabolite of IDA, 4-demethoxydaunorubicinol (idarubicinol, or IDOL), had cytotoxic activity and the ability to penetrate the blood-brain barrier.
  • For this reason, the Pediatric Oncology Group conducted a Phase 2 trial of IDA for children with recurrent or progressive brain tumors.
  • Patients were stratified by tumor types into 6 categories: stratum 1, low-grade astrocytoma; stratum 2, malignant glioma (glioblastoma multiforme and anaplastic astrocytoma); stratum 3, medulloblastoma; stratum 4, brainstem glioma; stratum 5, ependymoma; and stratum 6, miscellaneous malignant tumors not included in the previous diagnoses.
  • The systemic clearance data for IDA and IDOL were nearly identical to those published on patients with leukemia, and the plasma elimination of the IDOL metabolite was substantially longer than that of the parent drug IDA.
  • We conclude from this data and from that in nonhuman primates that it is unlikely that IDA, daunomycin, or other related anthracyclines will be useful for treating primary CNS tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Idarubicin / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14565163.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] ZRP63D75JW / Idarubicin
  • [Other-IDs] NLM/ PMC1920677
  •  go-up   go-down


15. Hattingen E, Blasel S, Nichtweiss M, Zanella FE, Weidauer S: MR imaging of midbrain pathologies. Clin Neuroradiol; 2010 Jun;20(2):81-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The spectrum of pathologic processes affecting the midbrain features some differences to other brain areas.
  • Primary midbrain tumors are also infrequent and often show a benign clinical course.
  • Apart from multiple sclerosis other inflammatory autoimmune processes and some infectious agents predominantly affect the brainstem including the midbrain.
  • [MeSH-major] Brain Stem Hemorrhage, Traumatic / diagnosis. Brain Stem Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Mesencephalon / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20532857.001).
  • [ISSN] 1869-1447
  • [Journal-full-title] Clinical neuroradiology
  • [ISO-abbreviation] Clin Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 103
  •  go-up   go-down


16. Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, Ioannidis JP: Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics; 2004 Jul;114(1):e111-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (4) primary nephrotoxicity, ie, any rise in serum creatinine or decrease in creatinine clearance with thresholds as defined in each study;.
  • (5) secondary nephrotoxicity, ie, urinary excretion of proteins or phospholipids; and (6) ototoxicity based on pure tone audiometry, brainstem auditory evoked responses, or otoacoustic emissions for neonates and infants, vestibular testing, clinical impression, or any other method.
  • NEPHROTOXICITY: There was no significant difference between ODD and MDD in the primary nephrotoxicity outcomes.
  • The pooled primary nephrotoxicity rates were 1.6% (15 of 955 cases) in the ODD arms and 1.6% (15 of 923 cases) in the MDD arms.
  • OTOTOXICITY: There was no significant difference between ODD and MDD in the primary ototoxicity outcomes.
  • SUBGROUP AND BIAS ANALYSES: We detected no statistically significant differences between ODD and MDD in any of the examined subgroups (neonatal intensive care unit, cystic fibrosis, cancer, or urinary tract infection), with respect to combined clinical or microbiologic failure outcomes, primary nephrotoxicity outcomes, or ototoxicity (based on auditory testing), when sufficient data were available.
  • In our meta-analysis, we were not able to show any reduction in the risk of primary nephrotoxicity outcomes with ODD.
  • CONCLUSIONS: Although single trials have been small, the available randomized evidence supports the general adoption of ODD of aminoglycosides in pediatric clinical practice.
  • This approach minimizes cost, simplifies administration, and provides similar or even potentially improved efficacy and safety, compared with MDD of these drugs.
  • [MeSH-major] Aminoglycosides / administration & dosage. Anti-Bacterial Agents / administration & dosage. Bacterial Infections / drug therapy
  • [MeSH-minor] Child. Cystic Fibrosis / drug therapy. Drug Administration Schedule. Hearing / drug effects. Humans. Infant, Newborn. Kidney / drug effects. Neoplasms / drug therapy. Randomized Controlled Trials as Topic. Risk. Treatment Outcome. Urinary Tract Infections / drug therapy

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2005 Apr;173(4):1192 [15758741.001]
  • [CommentIn] Pediatrics. 2005 Mar;115(3):827-8; author reply 828 [15741401.001]
  • (PMID = 15231982.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Anti-Bacterial Agents
  •  go-up   go-down


17. Rosso T, Aglioti SM, Zanette G, Ischia S, Finco G, Farina S, Fiaschi A, Tinazzi M: Functional plasticity in the human primary somatosensory cortex following acute lesion of the anterior lateral spinal cord: neurophysiological evidence of short-term cross-modal plasticity. Pain; 2003 Jan;101(1-2):117-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional plasticity in the human primary somatosensory cortex following acute lesion of the anterior lateral spinal cord: neurophysiological evidence of short-term cross-modal plasticity.
  • The primary somatosensory cortex (S1) in adult animals and humans is capable of rapid modification after deafferentation.
  • In this study the effect of the acute lesion of one ascending anterior lateral column on neuronal activity within the dorsal column-medial lemniscal system was assessed by recording somatosensory evoked potentials (SEPs) in seven patients who underwent unilateral percutaneous cervical cordotomy (PCC) as treatment for drug-resistant malignant pain.Spinal, brainstem and cortical SEPs were recorded 2h before and 3h after PCC by stimulating the posterior tibial nerve at both ankles.
  • No significant changes in spinal or brainstem potentials were observed.
  • [MeSH-minor] Aged. Aged, 80 and over. Cordotomy. Evoked Potentials, Somatosensory. Female. Functional Laterality. Hot Temperature. Humans. Male. Middle Aged. Neoplasms / complications. Pyramidal Tracts / physiology. Spinothalamic Tracts / physiology. Tibial Nerve / physiology. Touch

  • MedlinePlus Health Information. consumer health - Pain.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12507706.001).
  • [ISSN] 0304-3959
  • [Journal-full-title] Pain
  • [ISO-abbreviation] Pain
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down






Advertisement